Literature DB >> 26255239

Surgical Revascularization versus Percutaneous Coronary Intervention and Optimal Medical Therapy in Diabetic Patients with Multi-Vessel Coronary Artery Disease.

Gennaro Giustino1, George D Dangas2.   

Abstract

Coronary artery disease (CAD) is the leading cause of death in patients with diabetes mellitus (DM). Patients with DM and CAD undergoing revascularization with either a surgical or a percutaneous approach are at higher risk of adverse outcomes and mortality compared with non-DM patients. It is within this background that the optimal choice of revascularization is of critical importance in this high-risk population. The large FREEDOM trial randomized 1900 patients with DM and multivessel CAD to either revascularization with coronary artery by-pass graft (CABG) surgery or percutaneous coronary intervention (PCI). Compared with PCI, CABG significantly reduced the rates of death and myocardial infarction but was associated with a higher risk of stroke. In a real-world setting the decision-making process for the optimal revascularization strategy in these patients is challenging as many clinical factors may influence the decision to either pursue a surgical or a percutaneous revascularization. However, the current consensus is that CABG should be the preferred revascularization strategy in diabetic patients with extensive multivessel CAD.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CABG; Coronary artery disease; Diabetes mellitus; PCI; Revascularization

Mesh:

Substances:

Year:  2015        PMID: 26255239     DOI: 10.1016/j.pcad.2015.08.005

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  1 in total

1.  Body weight variability and cancer incidence in men aged 40 years and older-Korean National Insurance Service Cohort.

Authors:  Yu Jin Cho; Jin Seul Kawk; Hyung-Jin Yoon; Minseon Park
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.